Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review
- 30 June 2006
- journal article
- review article
- Published by Elsevier BV in Digestive and Liver Disease
- Vol. 38 (6), 363-373
- https://doi.org/10.1016/j.dld.2006.01.020
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- TipranavirDrugs, 2005
- AtazanavirDrugs, 2005
- Amprenavir or Fosamprenavir plus Ritonavir in HIV InfectionDrugs, 2005
- Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease InhibitorsClinical Infectious Diseases, 2004
- Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2000
- Risk Factors for Hepatotoxicity in HIV-1--Infected Patients Receiving Ritonavir and Saquinavir with or without StavudineClinical Infectious Diseases, 2000
- Elevated Liver Enzymes Following Initiation of Antiretroviral TherapyPublished by American Medical Association (AMA) ,2000
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Hepatitis B and C in HIV-infected patientsJournal of Hepatology, 1997
- Role of endogenous interferon in hepatitis C virus (HGV) infection and in coinfection by HIV and HCVResearch in Virology, 1996